| Abstract | OBJECTIVE: To investigate the efficacy of low dose of botulinum toxin type A (BTX-A) for facial synkinesis and hyperlacrimation. MATERIAL AND METHODS: Eleven patients suffering from facial synkinesis after Bell's palsy or facial nerve injury were treated with a low dose of BTX-A, 0.5-1.25 U per point into several points. One patient showing hyperlacrimation was also treated with BTX-A. The whole observational period was 43 months. RESULTS: On average, 5.76 U of BTX-A, which was lower than that of previous reports, was injected per treatment. In seven cases, synkinesis disappeared completely after three or fewer sessions of BTX-A injection. The mean interval between treatments was 14.5 weeks. Hyperlacrimation was completely suppressed after a single subcutaneous injection of BTX-A. Only mild subcutaneous hemorrhage was observed as adverse reactions. CONCLUSION: Facial synkinesis can be treated with a lower dose of BTX-A without relevant adverse reactions. |
| Authors | H Ito, H Ito, S Nakano, H Kusaka
(Affiliation: Department of Neurology, Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan. hishashi.ito at tokushukai.jp)
|
| Journal | Acta neurologica Scandinavica
(Acta Neurol Scand)
Vol. 115
Issue 4
Pg. 271-4
(Apr 2007)
ISSN: 0001-6314 Denmark |
| PMID | 17376126
(Publication Type: Clinical Trial, Journal Article)
|
| Chemical References |
- Botulinum Toxin Type A
- Neuromuscular Agents
|
| Topics |
- Adult
- Aged
- Aged, 80 and over
- Botulinum Toxin Type A
(administration & dosage)
- Dose-Response Relationship, Drug
- Female
- Humans
- Injections, Subcutaneous
- Lacrimal Apparatus Diseases
(drug therapy)
- Male
- Middle Aged
- Neuromuscular Agents
(administration & dosage)
- Prospective Studies
- Synkinesis
(drug therapy)
- Tears
(secretion)
- Treatment Outcome
|
